ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch

Company Expects Up To $40m From The Product In 2022

 
• By Chloe Kent
  
Close up of ANI sign at their Canadian head office in Oakville
ANI's share price took a hit following losses related to commercial expenses. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business